Free Trial
NASDAQ:TXG

10x Genomics (TXG) Stock Price, News & Analysis

$18.11
+1.41 (+8.44%)
(As of 07/22/2024 ET)
Today's Range
$17.10
$18.14
50-Day Range
$15.71
$26.56
52-Week Range
$15.28
$63.57
Volume
2.96 million shs
Average Volume
1.64 million shs
Market Capitalization
$2.16 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.57

10x Genomics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.36 Rating Score
Upside/​Downside
107.5% Upside
$37.57 Price Target
Short Interest
Bearish
8.96% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.73
Upright™ Environmental Score
News Sentiment
0.18mentions of 10x Genomics in the last 14 days
Based on 16 Articles This Week
Insider Trading
Selling Shares
$289,170 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.53) to ($0.92) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.50 out of 5 stars

Medical Sector

107th out of 894 stocks

Analytical Instruments Industry

5th out of 26 stocks

TXG stock logo

About 10x Genomics Stock (NASDAQ:TXG)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

TXG Stock Price History

TXG Stock News Headlines

research and developement concept background scientist or reseacher using microscope in biotechnology laboratory  overlay with DNA strand and molecules symbo; . concept of DNA engineering
Strategic Buy Lights Up This Biotech Stock: Time to Invest? (TXG)
Life sciences company Illumina Inc. (NASDAQ: ILMN) stock surged over 10% following its announcement of the acquisition of Fluent Biosciences.
270x more lucrative than NVIDIA???
Is the AI boom losing steam? According to the Wall Street Journal, the pace of innovation in AI is slowing down... Its usefulness is limited... And the cost of running AI remains "exorbitant."
10x Genomics (NASDAQ:TXG) Shares Gap Up to $16.70
10x Genomics (NASDAQ:TXG) PT Lowered to $25.00
270x more lucrative than NVIDIA???
Is the AI boom losing steam? According to the Wall Street Journal, the pace of innovation in AI is slowing down... Its usefulness is limited... And the cost of running AI remains "exorbitant."
See More Headlines
Receive TXG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 10x Genomics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/30/2024
Today
7/23/2024
Next Earnings (Confirmed)
8/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:TXG
Fax
N/A
Employees
1,259
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$37.57
High Stock Price Target
$75.00
Low Stock Price Target
$16.00
Potential Upside/Downside
+107.5%
Consensus Rating
Hold
Rating Score (0-4)
2.36
Research Coverage
14 Analysts

Profitability

Net Income
$-255,100,000.00
Pretax Margin
-41.08%

Debt

Sales & Book Value

Annual Sales
$618.73 million
Book Value
$6.22 per share

Miscellaneous

Free Float
107,215,000
Market Cap
$2.16 billion
Optionable
Optionable
Beta
1.84
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Serge Saxonov Ph.D. (Age 47)
    Co-Founder, CEO & Director
    Comp: $837.68k
  • Dr. Benjamin J. Hindson Ph.D. (Age 49)
    Co-Founder, President, Chief Scientific Officer & Director
    Comp: $615.96k
  • Mr. Justin J. McAnearMr. Justin J. McAnear (Age 48)
    Chief Financial Officer
    Comp: $535.91k
  • Mr. Eric S. Whitaker Esq. (Age 57)
    Chief Legal Officer
    Comp: $558.97k
  • Mr. Michael Schnall-Levin
    Founding Scientist & CTO
  • Ms. Cassie Corneau
    Manager of Investor Relations and Strategic Finance
  • Ms. Rebecca Port
    Chief People Officer

TXG Stock Analysis - Frequently Asked Questions

How have TXG shares performed this year?

10x Genomics' stock was trading at $55.96 at the beginning of 2024. Since then, TXG shares have decreased by 67.6% and is now trading at $18.11.
View the best growth stocks for 2024 here
.

How were 10x Genomics' earnings last quarter?

10x Genomics, Inc. (NASDAQ:TXG) posted its earnings results on Tuesday, April, 30th. The company reported ($0.50) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.50). The firm's revenue was up 5.0% on a year-over-year basis.

What is Serge Saxonov's approval rating as 10x Genomics' CEO?

25 employees have rated 10x Genomics Chief Executive Officer Serge Saxonov on Glassdoor.com. Serge Saxonov has an approval rating of 100% among the company's employees. This puts Serge Saxonov in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When did 10x Genomics IPO?

10x Genomics (TXG) raised $297 million in an IPO on Thursday, September 12th 2019. The company issued 9,000,000 shares at $31.00-$35.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen was co-manager.

Who are 10x Genomics' major shareholders?

10x Genomics' top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (5.15%), SG Americas Securities LLC (0.09%), Mirador Capital Partners LP (0.05%) and SteelPeak Wealth LLC (0.02%). Insiders that own company stock include Serge Saxonov, Benjamin J Hindson, John R Stuelpnagel, Mathai Mammen, Justin J Mcanear, James Wilbur, Sridhar Kosaraju and Bradford Crutchfield.
View institutional ownership trends
.

How do I buy shares of 10x Genomics?

Shares of TXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TXG) was last updated on 7/23/2024 by MarketBeat.com Staff

From Our Partners